Shopping Cart
Remove All
Your shopping cart is currently empty
Pateclizumab (Synonyms: RG7416, RG 7416, PRO283698, PRO 283698, MLTA3698A, MLTA 3698A)
Catalog No. T77366 Copy Product Info
🥰Excellent
Pateclizumab (MLTA3698A) is a humanized monoclonal antibody targeting lymphotoxin α (LTα), which can be used to study rheumatoid arthritis.
Pateclizumab
Copy Product Info🥰Excellent
Catalog No. T77366
Synonyms RG7416, RG 7416, PRO283698, PRO 283698, MLTA3698A, MLTA 3698A
Pateclizumab (MLTA3698A) is a humanized monoclonal antibody targeting lymphotoxin α (LTα), which can be used to study rheumatoid arthritis.
Pateclizumab
Cas No. 1202526-59-7
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $415 | - | In Stock | |
| 5 mg | $1,245 | - | In Stock | |
| 10 mg | $1,992 | - | In Stock | |
| 25 mg | $3,386 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:96.96% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Pateclizumab (MLTA3698A) is a humanized monoclonal antibody targeting lymphotoxin α (LTα), which can be used to study rheumatoid arthritis. |
| In vitro | Pateclizumab is a human immunoglobulin G1 (IgG1) monoclonal antibody. By blocking the binding of Lα3 to TNFRII and Lα1β2 to Lβr, the IC50 was 0.29 nM and 0.31 nM, respectively. [1] |
| In vivo | In cynomolgus monkeys treated with pateclizumab (5, 15, 50 mg/kg), the ratio of fetal to maternal serum concentration was 0.73% on GD 50 and 61% on GD 139. Taking Pateclizumab between the 20th and 132nd days of gestation does not induce maternal or fetal developmental toxicity. [1] |
| Synonyms | RG7416, RG 7416, PRO283698, PRO 283698, MLTA3698A, MLTA 3698A |
| Reactivity | Human |
| Verified Activity | Immobilized human TNFSF1/TNFb Protein (His) at 2 μg/mL can bind Pateclizumab. The EC50 is 0.01351 μg/mL.  |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | TNFSF1/TNFb/ LT alpha |
| Molecular Weight | 144.9 kDa |
| Cas No. | 1202526-59-7 |
| Isotype | Human IgG1 kappa |
| Recommended Isotype Control |
| Storage | -20°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Pateclizumab | purchase Pateclizumab | Pateclizumab cost | order Pateclizumab | Pateclizumab in vivo | Pateclizumab in vitro | Pateclizumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.